🔴 Outlook Therapeutics is trading 10.1% down today after $9 thousand in third-quarter revenue

Outlook Therapeutics is trading at $0.68, down 10.1% now, after its August 14 earnings release showed only $9 thousand in third-quarter revenue.

• The U.S. LYTENAVA launch remains targeted for late 2026.
• The company priced a $55 million stock-and-warrant offering at $0.99 per share, creating substantial dilution pressure.
• The decline follows two consecutive sharp drops after earnings and financing news.